Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 27:73:563-574.
doi: 10.1146/annurev-med-042120-020148.

Clinical Phenotypes of Cystic Fibrosis Carriers

Affiliations
Review

Clinical Phenotypes of Cystic Fibrosis Carriers

Philip M Polgreen et al. Annu Rev Med. .

Abstract

Cystic fibrosis (CF) is an autosomal recessive genetic disorder caused by mutations in CFTR, the cystic fibrosis transmembrane conductance regulator gene. People with CF experience a wide variety of medical conditions that affect the pulmonary, endocrine, gastrointestinal, pancreatic, biliary, and reproductive systems. Traditionally, CF carriers, with one defective copy of CFTR, were not thought to be at risk for CF-associated diseases. However, an emerging body of literature suggests that heterozygotes are at increased risk for many of the same conditions as homozygotes. For example, heterozygotes appear to be at increased risk for chronic pancreatitis, atypical mycobacterial infections, and bronchiectasis. In the United States alone, there are almost 10 million CF carriers. Universal newborn screening and prenatal genetic screening will identify more. Thus, there is a critical need to develop more precise estimates of health risks attributable to the CF carrier state across the lifespan.

Keywords: CFTR; carrier; cystic fibrosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CF-related conditions for which CF carriers may be at increased risk. The figure summarizes results from Reference 4. Abbreviations: CF, cystic fibrosis; GI, gastrointestinal.
Figure 2.
Figure 2.
Factors potentially modifying cystic fibrosis (CF) carrier phenotypes.

References

    1. Stoltz DA, Meyerholz DK, Welsh MJ. 2015. Origins of cystic fibrosis lung disease. N. Engl. J. Med. 372:351–62 - PMC - PubMed
    1. Elborn JS. 2016. Cystic fibrosis. Lancet 388:2519–31 - PubMed
    1. O’Sullivan BP, Freedman SD. 2009. Cystic fibrosis. Lancet 373:1891–904 - PubMed
    1. Miller AC, Comellas AP, Hornick DB, et al. 2019. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. PNAS 117:1621–27 - PMC - PubMed
    1. Burke D, Harrison M, Fleming C, et al. 2017. Clostridium difficile carriage in adult cystic fibrosis (CF); implications for patients with CF and the potential for transmission of nosocomial infection. J. Cyst. Fibrosis 16:291–98 - PubMed

Publication types